Philogen posts record 2025 profit on RayzeBio deal, plans dividend and R&D push

An announcement from Philogen SpA ( (IT:PHIL) ) is now available.

Philogen reported record 2025 results, with net profit surging to €229.7 million and revenue from contracts with customers jumping more than fourfold to €314.3 million, largely driven by a major upfront payment from a licensing deal with Bristol Myers Squibb’s RayzeBio unit for a prostate cancer candidate. The group’s EBITDA expanded to €261.6 million, its net financial position turned strongly positive at €368.3 million, and the board will propose allocating 2025 profit to a non-distributable reserve while funding a €0.70 per-share dividend from existing reserves, alongside seeking shareholder approval for its remuneration report and a new treasury share buyback authorization.

Management signalled that the strengthened balance sheet will support broader R&D and manufacturing investment, including seven new potentially registration-enabling studies by 2027 and multiple Phase I trials, underlining Philogen’s ambition to accelerate its pipeline toward commercialisation despite the absence of marketed products. The company is also expanding its artificial intelligence capabilities to boost operational efficiency and drug discovery, a move that could enhance its competitive position in biotech partnering as it continues to monetise its discovery platforms through high-value licensing agreements.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR24.50 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

More about Philogen SpA

Philogen S.p.A. is an Italian biotechnology group, together with its Swiss subsidiary Philochem AG, focused on discovering and developing antibody-based drugs and small organic molecules, particularly in oncology. Operating without products yet on the market, it generates revenue mainly from upfront payments, milestones and collaboration agreements with larger pharmaceutical partners, alongside contract research and manufacturing services.

Average Trading Volume: 17,818

Technical Sentiment Signal: Strong Buy

Current Market Cap: €643.3M

See more insights into PHIL stock on TipRanks’ Stock Analysis page.